Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CN9D
|
|||
| Drug Name |
Anetumab ravtansine
|
|||
| Synonyms |
Mesothelin-ADC
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Malignant pleural mesothelioma [ICD-11: 2C26.0; ICD-9: 163] | Phase 2 | [1] | |
| Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 2 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [4] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | ||
| Company |
Bayer Pharmaceuticals Whippany, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT03926143) A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.